NovaBridge Biosciences
NBP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NBP
NovaBridge Biosciences (NBP) is a clinical-stage biotechnology company focused on developing a pipeline of drug candidates, including givastomig, ragistomig, uliledlimab, and VIS-101, with no approved products or product revenue to date [sec].
Key risk: No approved products or revenue
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 1 catalyst for NovaBridge Biosciences.
NovaBridge Biosciences (NBP) is a clinical-stage biotechnology company focused on developing a pipeline of drug candidates, including givastomig, ragistomig, uliledlimab, and VIS-101, with no approved products or product revenue to date [sec].
- Pipeline consists of four clinical-stage drug candidates: givastomig, ragistomig, uliledlimab, and VIS-101 [sec · filed 2026-01-22].
- No products have been approved for commercial sale, and the company has not generated any revenue from product sales [sec · filed 2025-12-18].
- Reported net losses of $88.3 million in 2025, $22.2 million in 2024, and $207.7 million in 2023 [sec · filed 2026-04-07].
- Cash and equivalents of $210.6M and shareholders' equity of $201.2M as of 2025-12-31 [sec].
- The company divested its Greater China assets and business operations in February 2024 [sec · filed 2025-12-18].
What works
- The company has a pipeline of four clinical-stage drug candidates, indicating ongoing research and development activity [sec · filed 2026-01-22].
- Cash and equivalents of $210.6M as of 2025-12-31 provide a financial cushion for continued operations [sec].
- The company may out-license certain rights of drug candidates after validating clinical safety and efficacy, potentially generating revenue [sec · filed 2025-12-18].
What to weigh
- The company has no approved products and has never generated revenue from product sales [sec · filed 2025-12-18].
- Substantial net losses have been incurred, with $88.3 million in 2025 alone, primarily from R&D and administrative costs [sec · filed 2026-04-07].
- Drug candidates may fail to demonstrate efficacy or safety, and the company faces risks of clinical trial setbacks common in the industry [sec · filed 2026-04-07].
- Limited financial and managerial resources may force the company to forgo or delay pursuit of potentially more valuable opportunities [sec · filed 2026-04-07].
From the filings
Quoted directly from source documents.
The company has no approved products and no product revenue.
“Although we currently do not have any product approved for commercial sale and have not generated any revenue from product sales”
SEC filings · December 18, 2025
Net losses for recent years.
“we incurred net losses of $88.3 million, $22.2 million and $207.7 million in 2025, 2024 and 2023, respectively.”
SEC filings · April 7, 2026
Pipeline includes four clinical-stage candidates.
“Our pipeline consists of four clinical stage drug candidates.”
SEC filings · December 18, 2025
Risk of clinical trial failure despite earlier promise.
“A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to a lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials.”
SEC filings · April 7, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · vis-101 — Phase 2 Readout: vis-101 — Topline results from the Phase 2 trial of VIS-101 are expected, which will inform further development and potential regulatory path.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — The company has no approved products and has never generated product revenue, relying on funding and collaborations [sec · filed 2025-12-18].
- Clinical trial failure risk — Drug candidates may fail to demonstrate efficacy or safety, with industry precedent of setbacks in advanced trials [sec · filed 2026-04-07].
- Substantial net losses — Net losses of $88.3M in 2025, $22.2M in 2024, and $207.7M in 2023, primarily from R&D and administrative costs [sec · filed 2026-04-07].
- Limited resource allocation — Limited financial and managerial resources may cause the company to forgo or delay pursuit of potentially more valuable opportunities [sec · filed 2026-04-07].
What to watch
- Phase 2 topline results for VIS-101, expected by 2026-12-31 [catalyst].
- Progress of clinical trials for givastomig, ragistomig, and uliledlimab [sec · filed 2026-01-22].
- Any out-licensing deals or collaborations that could generate revenue [sec · filed 2025-12-18].
- Regulatory decisions on clinical trial applications or approvals [sec · filed 2026-04-07].
Sources: SEC filings · Generated August 27, 2026 · How we verify sources →
Run NovaBridge Biosciences through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NovaBridge Biosciences facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.13
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~123d
1 buy · 4 sells (180d)
Catalysts
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
45
Total value held
$71.4M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 12,065,300 | $29.6M |
| hhlr advisors, ltd. | 5,980,568 | $14.7M |
| morgan stanley | 3,838,198 | $9.4M |
| aihc capital management ltd | 2,262,933 | $5.6M |
| adage capital partners gp, l.l.c. | 1,000,000 | $2.5M |
| blackrock, inc. | 627,496 | $1.5M |
| exome asset management llc | 576,960 | $1.4M |
| state street corp | 370,107 | $910K |
| fiera capital corp | 315,681 | $777K |
| barclays plc | 299,299 | $736K |
Showing top 10 of 45 institutional holders of NovaBridge Biosciences. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 8.3%
- Days to cover
- 4.6
- Shares short
- 4,336,667
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NBP short interestFrequently asked questions
What is the AI investment thesis for NovaBridge Biosciences?
NovaBridge Biosciences (NBP) is a clinical-stage biotechnology company focused on developing a pipeline of drug candidates, including givastomig, ragistomig, uliledlimab, and VIS-101, with no approved products or product revenue to date [sec].
What is NovaBridge Biosciences's next catalyst?
NovaBridge Biosciences's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: vis-101" — expected December 31, 2026.
Who is the CEO of NovaBridge Biosciences?
Dr. Srishti Gupta M.D. is the chief executive officer of NovaBridge Biosciences (NBP).
Where is NovaBridge Biosciences headquartered?
NovaBridge Biosciences (NBP) is headquartered in Rockville, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.